Skip to main content

MIMEDX GROUP, INC. (MDXG) Stock Forecast 2025 - AI Price Prediction & Analysis


MIMEDX GROUP, INC. (MDXG) AI Stock Price Forecast & Investment Analysis

MIMEDX GROUP, INC. Stock Price Chart and Technical Analysis

Loading MIMEDX GROUP, INC. interactive price chart and technical analysis...

MIMEDX GROUP, INC. (MDXG) - Comprehensive Stock Analysis & Investment Research

Deep dive into MIMEDX GROUP, INC.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about MIMEDX GROUP, INC., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For MIMEDX GROUP, INC.: MIMEDX GROUP, INC. operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

MIMEDX GROUP, INC. (Stock Symbol: MDXG) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 863 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing MIMEDX GROUP, INC.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For MIMEDX GROUP, INC.: With $363M in annual revenue and -4.9% net margin, the company demonstrates developing profitability.

Annual Revenue: $363 million generating a -4.9% net profit margin .

Market Capitalization: $1050 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -994.0% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for MIMEDX GROUP, INC. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For MIMEDX GROUP, INC.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for MIMEDX GROUP, INC. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: MIMEDX GROUP, INC.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For MIMEDX GROUP, INC.: Market positioning analysis based on available financial and operational metrics.

MIMEDX GROUP, INC. strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 83.1% gross margin, indicating strong pricing power and operational efficiency.

MIMEDX GROUP, INC. (MDXG) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for MIMEDX GROUP, INC. stock analysis.

Loading MIMEDX GROUP, INC. comprehensive fundamental analysis and insider trading data...

Deep dive into MIMEDX GROUP, INC.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if MIMEDX GROUP, INC. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For MIMEDX GROUP, INC.: With a P/E ratio of 32.63, the market highly values future growth prospects.

P/E Ratio 32.63x
P/B Ratio 4.85x
Market Cap $1050M
EPS $0.22
Book Value/Share $1.45
Revenue/Share $2.43
FCF/Share $-0.42
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently MIMEDX GROUP, INC. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For MIMEDX GROUP, INC.: An ROE of -994.0% indicates room for improvement in shareholder value creation.

ROE -994.0%
ROA -6.9%
ROIC -68.4%
Gross Margin 83.1%
Operating Margin -2.9%
Net Margin -4.9%
EBT Margin -4.7%
Tax Rate 33.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess MIMEDX GROUP, INC.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For MIMEDX GROUP, INC.: A current ratio of 3.71 indicates strong liquidity.

Current Ratio 3.71x
Quick Ratio 3.12x
D/E Ratio 586.91x
Financial Leverage 2291.82x
Interest Coverage -1.6x
Working Capital $101M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal MIMEDX GROUP, INC.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For MIMEDX GROUP, INC.: Free cash flow of $-7M indicates cash challenges that need attention.

Operating Cash Flow $-6M
Free Cash Flow $-7M
Capital Spending $-2M
OCF Growth YoY -43.1%
FCF Growth YoY -55.2%
FCF/Sales -2.8%
CapEx/Sales 0.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively MIMEDX GROUP, INC. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For MIMEDX GROUP, INC.: An asset turnover of 1.41x demonstrates efficient asset utilization.

Asset Turnover 1.41x
Receivables Turnover 7.1x
Inventory Turnover 3.5x
Fixed Assets Turnover 18.6x
Days Sales Outstanding 52 days
Days Inventory 104 days
Payables Period 63 days
Cash Conversion Cycle 92 days
Understanding Financial Statement Data

What these metrics mean: Key figures from MIMEDX GROUP, INC.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For MIMEDX GROUP, INC.: With annual revenue of $363M, MIMEDX GROUP, INC. demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $363M
R&D Expense $3M
SG&A Expense $79M
Cost of Goods Sold $57M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 78%
Cash & Short-term Investments 43%
Total Liabilities 51%
Short-term Debt 2%
Accounts Receivable 22%
Inventory 8%
Dividend & Shareholder Information
Shares Outstanding 150M
Growth Metrics (YoY)
EPS Growth 7.2%

Latest MIMEDX GROUP, INC. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting MIMEDX GROUP, INC. (MDXG) stock price and investment outlook.

, source: Seeking Alpha

Good afternoon and thank you for standing by. Welcome to the MiMedx Second Quarter 2023 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only mode. A ...

, source: Morningstar

MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the ...

, source: Business Insider

MiMedx Group Inc. ( (MDXG)) has realeased its Q3 earnings. Here is a breakdown of the information MiMedx Group Inc. presented to its investors. MiMedx Group Inc., a leader in placental tissue products ...

, source: MarketWatch

Dorothy E. Puhy currently works at Blue Cross & Blue Shield of Massachusetts, Inc., as Chairman from 2020, Crico Strategies, as Director, and MiMedx Group, Inc., as Independent Director from 2024. Ms.

MIMEDX GROUP, INC. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of MIMEDX GROUP, INC. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $26M x 3.0x
ALUR Unlock Forecast - 30 Days FREE Trial $17M -0.4x -0.3x
ANGO Unlock Forecast - 30 Days FREE Trial $442M -1.4x 2.4x
ANIK Unlock Forecast - 30 Days FREE Trial $128M -4.3x 0.9x
AORT Unlock Forecast - 30 Days FREE Trial $1805M -198.2x 4.3x
APYX Unlock Forecast - 30 Days FREE Trial $89M -3.5x 12.3x
ATEC Unlock Forecast - 30 Days FREE Trial $2274M -7.4x 95.7x
ATRC Unlock Forecast - 30 Days FREE Trial $1810M -39.6x 3.9x
AVHHL Unlock Forecast - 30 Days FREE Trial $27M x x
BAX Unlock Forecast - 30 Days FREE Trial $12132M -94.9x 1.7x
BBNX Unlock Forecast - 30 Days FREE Trial $976M x 3.2x
BDX Unlock Forecast - 30 Days FREE Trial $53749M 33.9x 2.1x
BEAT Unlock Forecast - 30 Days FREE Trial $57M -5.7x 13.8x
BJDX Unlock Forecast - 30 Days FREE Trial $2M -0.5x 0.4x
BSX Unlock Forecast - 30 Days FREE Trial $144402M 57.6x 6.4x
BVS Unlock Forecast - 30 Days FREE Trial $595M -18.3x 3.7x
CARL Unlock Forecast - 30 Days FREE Trial $-20M x x
CLPT Unlock Forecast - 30 Days FREE Trial $318M -23.5x 16.1x
CODX Unlock Forecast - 30 Days FREE Trial $16M -0.7x 0.4x
CVRX Unlock Forecast - 30 Days FREE Trial $187M -5.5x 3.2x
DCTH Unlock Forecast - 30 Days FREE Trial $460M 206.2x 4.4x
DRTS Unlock Forecast - 30 Days FREE Trial $348M x 4.0x
DXCM Unlock Forecast - 30 Days FREE Trial $30903M 54.1x 12.0x
EBRCZ Unlock Forecast - 30 Days FREE Trial $337M x 6.8x
FEMY Unlock Forecast - 30 Days FREE Trial $11M -1.4x 7.6x
FOFA Unlock Forecast - 30 Days FREE Trial $8M x 14.6x
GIPL Unlock Forecast - 30 Days FREE Trial $5M x 25.6x
GKOS Unlock Forecast - 30 Days FREE Trial $4914M -46.3x 6.4x
GMED Unlock Forecast - 30 Days FREE Trial $7839M 22.0x 1.8x
HRGN Unlock Forecast - 30 Days FREE Trial $31M x 40.6x
IART Unlock Forecast - 30 Days FREE Trial $1099M 200.2x 1.1x
ICCM Unlock Forecast - 30 Days FREE Trial $62M x 21.3x
ICUI Unlock Forecast - 30 Days FREE Trial $3248M -49.8x 1.6x
IDXG Unlock Forecast - 30 Days FREE Trial $23M 4.4x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $30M x 7.0x
IINNW Unlock Forecast - 30 Days FREE Trial $8M x 1.9x
INBS Unlock Forecast - 30 Days FREE Trial $9M -0.3x 3.0x
INFU Unlock Forecast - 30 Days FREE Trial $213M 42.0x 3.9x
INSP Unlock Forecast - 30 Days FREE Trial $2365M 44.5x 3.5x
IRMD Unlock Forecast - 30 Days FREE Trial $905M 43.8x 9.6x
IRTC Unlock Forecast - 30 Days FREE Trial $5663M -20.2x 54.6x
KIDS Unlock Forecast - 30 Days FREE Trial $448M -20.7x 1.3x
KMTS Unlock Forecast - 30 Days FREE Trial $1350M x x
KRMD Unlock Forecast - 30 Days FREE Trial $192M -19.8x 11.6x
LNSR Unlock Forecast - 30 Days FREE Trial $59M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $111M -0.6x 14.1x
LUNG Unlock Forecast - 30 Days FREE Trial $69M -4.3x 1.0x
MCAG Unlock Forecast - 30 Days FREE Trial $22M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $21M x -9.9x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.8x 13.4x
MDXG Unlock Forecast - 30 Days FREE Trial $1050M 32.6x 4.9x
MGRM Unlock Forecast - 30 Days FREE Trial $211M -10.7x 24.5x
MHUA Unlock Forecast - 30 Days FREE Trial $13M x 0.1x
MMM Unlock Forecast - 30 Days FREE Trial $85312M 21.7x 19.9x
MMSI Unlock Forecast - 30 Days FREE Trial $5093M 42.8x 3.4x
NEPH Unlock Forecast - 30 Days FREE Trial $39M -20.3x 2.0x
NMTC Unlock Forecast - 30 Days FREE Trial $46M -1.7x 5.7x
NPCE Unlock Forecast - 30 Days FREE Trial $328M -10.4x 16.9x
NSPR Unlock Forecast - 30 Days FREE Trial $124M -4.3x 6.1x
NVCR Unlock Forecast - 30 Days FREE Trial $1419M -20.8x 4.1x
NXGL Unlock Forecast - 30 Days FREE Trial $22M -6.8x 4.6x
OBIO Unlock Forecast - 30 Days FREE Trial $118M -3.4x 2.0x
OFIX Unlock Forecast - 30 Days FREE Trial $581M -5.8x 1.3x
OSRH Unlock Forecast - 30 Days FREE Trial $25M x 0.3x
OSUR Unlock Forecast - 30 Days FREE Trial $253M 17.1x 0.7x
PAVM Unlock Forecast - 30 Days FREE Trial $20M 0.3x 0.5x
PDEX Unlock Forecast - 30 Days FREE Trial $115M 12.9x 3.2x
PEN Unlock Forecast - 30 Days FREE Trial $10023M 67.9x 7.8x
PLRZ Unlock Forecast - 30 Days FREE Trial $7M x 0.4x
PMI Unlock Forecast - 30 Days FREE Trial $44M x x
PODD Unlock Forecast - 30 Days FREE Trial $23559M 99.8x 16.1x
PRCT Unlock Forecast - 30 Days FREE Trial $2075M -45.4x 5.4x
PROF Unlock Forecast - 30 Days FREE Trial $130M x 3.3x
PYPD Unlock Forecast - 30 Days FREE Trial $54M x 2.6x
RCEL Unlock Forecast - 30 Days FREE Trial $145M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $42M x 15.8x
RMD Unlock Forecast - 30 Days FREE Trial $40361M 28.8x 6.8x
RSMDF Unlock Forecast - 30 Days FREE Trial $3663M 2.6x 0.6x
RTGN Unlock Forecast - 30 Days FREE Trial $66M x x
RVP Unlock Forecast - 30 Days FREE Trial $25M -0.9x 0.3x
SGHT Unlock Forecast - 30 Days FREE Trial $187M -3.7x 2.7x
SIBN Unlock Forecast - 30 Days FREE Trial $628M -14.3x 3.7x
SKIN Unlock Forecast - 30 Days FREE Trial $321M -1.8x 4.3x
SNOA Unlock Forecast - 30 Days FREE Trial $7M -5.6x 1.7x
SNWV Unlock Forecast - 30 Days FREE Trial $299M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $13015M 34.3x 3.6x
SRTS Unlock Forecast - 30 Days FREE Trial $51M 31.6x 1.0x
SSKN Unlock Forecast - 30 Days FREE Trial $7M -8.0x 21.3x
STIM Unlock Forecast - 30 Days FREE Trial $213M -1.0x 7.9x
STME Unlock Forecast - 30 Days FREE Trial $12M x x
STSS Unlock Forecast - 30 Days FREE Trial $8M -2.5x 0.6x
SYK Unlock Forecast - 30 Days FREE Trial $140684M 42.0x 12.0x
TCMD Unlock Forecast - 30 Days FREE Trial $333M 22.0x 1.7x
TELA Unlock Forecast - 30 Days FREE Trial $73M -1.8x 8.0x
TFX Unlock Forecast - 30 Days FREE Trial $5676M 29.6x 1.3x
TNDM Unlock Forecast - 30 Days FREE Trial $849M -17.1x 6.4x
TNON Unlock Forecast - 30 Days FREE Trial $10M -0.3x 1.4x
USAQ Unlock Forecast - 30 Days FREE Trial $2M x x
UTMD Unlock Forecast - 30 Days FREE Trial $204M 16.2x 1.7x
VERO Unlock Forecast - 30 Days FREE Trial $5M 0.0x 2.2x
WST Unlock Forecast - 30 Days FREE Trial $18563M 38.1x 6.3x
XTNT Unlock Forecast - 30 Days FREE Trial $96M -478.8x 2.0x

Frequently Asked Questions - MIMEDX GROUP, INC. Stock Forecast

How accurate are MIMEDX GROUP, INC. stock predictions?

Our AI model demonstrates 27% historical accuracy for MDXG predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence MIMEDX GROUP, INC. stock price forecasts?

Our analysis considers MIMEDX GROUP, INC.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is MIMEDX GROUP, INC. a good investment in 2025?

Based on our AI analysis, MIMEDX GROUP, INC. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are MIMEDX GROUP, INC. forecasts updated?

MIMEDX GROUP, INC. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced MIMEDX GROUP, INC. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for MIMEDX GROUP, INC. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...